Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

ImmunosuppressantsRituximabNormal dose based on indicationAdminister Anytime During HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
143860N/A30-400 (variable by dose)N/AN/A0.04N/A0 (N/A)


  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00073
  • Jillella A, Dainer P, Kallab A, Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. American journal of hematology 2002; 71(3), 219-22.
  • Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. British journal of haematology 2002; 116(1), 229-35.
  • Vieira C, Agarwal A, Book B et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77(4), 542-548.